Glycerol Phenylbutyrate
Brand name: Ravicti
Rank #369 of 500 drugs by total cost
$26.6M
Total Cost
268
Total Claims
$26.6M
Total Cost
15
Prescribers
$99K
Cost per Claim
0
Beneficiaries
278
30-Day Fills
$1.8M
Avg Cost/Provider
18
Avg Claims/Provider
About Glycerol Phenylbutyrate
Glycerol Phenylbutyrate (sold as Ravicti) was prescribed 268 times by 15 Medicare Part D providers in 2023, costing the program $26.6M. At $99K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 366 | Dofetilide (Dofetilide) | $26.7M | 98,814 |
| 367 | Plecanatide (Trulance) | $26.6M | 36,026 |
| 368 | Ursodiol (Ursodiol) | $26.6M | 123,719 |
| 369 | Glycerol Phenylbutyrate (Ravicti) | $26.6M | 268 |
| 370 | Doravirine (Pifeltro) | $26.4M | 14,437 |
| 371 | Brinzolamide/Brimonidine Tart (Simbrinza) | $26.3M | 97,240 |
| 372 | Rotigotine (Neupro) | $26.2M | 23,665 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology